title: Dupilumab for the treatment of atopic dermatitis: A clinical trial review.
abstract: BACKGROUND
  Current treatment options for moderate-to-severe atopic dermatitis (AD) are limited and have potentially dangerous side effects. Dupilumab is a novel monoclonal antibody that was recently studied in adult patients with moderate-to-severe AD. Dupilumab inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling and was previously found to be effective in asthma. Considering that both AD and asthma are Th2 cell-mediated inflammatory processes, it is reasonable to suspect that dupilumab would be beneficial in AD.`
  
  
  METHODS
  This article is a review of the one major clinical trial that assessed the efficacy of dupilumab in patients with AD. Its goal is to provide a comparison to the current modalities for the treatment of AD and expert insight regarding future studies.
  
  
  CONCLUSIONS
  The results of this study are a significant therapeutic advancement. Dupilumab was shown to provide a mean percent change in Eczema Area and Severity Index score of -74% ± 3.6, in addition to, statistically and clinically significant reductions the severity, symptomatology, and morbidity associated with AD. However, the small sample size makes it difficult to assess the magnitude of this effect. As a result, dupilumab will likely be reserved for cases of severe AD unresponsive to traditional modalities.
authors.affiliation: a 1 Wake Forest School of Medicine, Center for Dermatology Research, Medical Center Boulevard, Department of Dermatology , Winston-Salem, NC, USA +1 33 67 16 77 40 ; +1 33 67 16 77 32 ; sfeldman@wakehealth.edu.
authors.forename: Sean
authors.initials: S
authors.lastname: McGregor
authors.affiliation: a 1 Wake Forest School of Medicine, Center for Dermatology Research, Medical Center Boulevard, Department of Dermatology , Winston-Salem, NC, USA +1 33 67 16 77 40 ; +1 33 67 16 77 32 ; sfeldman@wakehealth.edu.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Farhangian
authors.affiliation: a 1 Wake Forest School of Medicine, Center for Dermatology Research, Medical Center Boulevard, Department of Dermatology , Winston-Salem, NC, USA +1 33 67 16 77 40 ; +1 33 67 16 77 32 ; sfeldman@wakehealth.edu.|b 2 Wake Forest School of Medicine, Department of Pathology , Winston-Salem, NC, USA.|c 3 Wake Forest School of Medicine, Department of Public Health Sciences , Winston-Salem, NC, USA.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy / Q000473:pathology; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018793:Interleukin-13 / Q000276:immunology / Q000378:metabolism; D015847:Interleukin-4 / Q000276:immunology / Q000378:metabolism; D012720:Severity of Illness Index; D018418:Th2 Cells / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C508598:IL4 protein, human; D018793:Interleukin-13; D015847:Interleukin-4; C582203:dupilumab
keywords: eczema; interleukin-13; interleukin-4; itch; pruritus; quality of life; sleep